Gilead Sciences, Inc.

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops, and commercializes medicines in areas of unmet medical need globally. Its key products include Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and Yeztugo for the treatment of HIV-1 infection. For hepatitis, it offers Epclusa (chronic hepatitis C virus), Livdelzi (primary biliary cholangitis), and Vemlidy (chronic hepatitis B virus). The company also has a portfolio of cell therapies: Tecartus and Yescarta (CAR T-cell therapies for adult patients) and Trodelvy (an injection for intravenous use). Additionally, it provides AmBisome for serious invasive fungal infections and Veklury for COVID-19. Gilead is also developing various immunotherapies for cancer and incurable diseases.

Gilead Sciences, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol GILD. The stock is traded in United States Dollars (USD), as the company is based in the United States. The exchange is one of the major US stock exchanges, providing liquidity and visibility for the company's shares.

Gilead Sciences operates in the Healthcare sector, specifically within the Drug Manufacturers - General industry. This classification reflects its role as a biopharmaceutical company that develops and manufactures a broad range of medicines, including antivirals for HIV and hepatitis, cell therapies for cancer, and treatments for fungal infections and COVID-19. The 'General' designation indicates that it is not limited to a specific drug type, such as generics or specialty pharmaceuticals.

Gilead Sciences is headquartered in the United States, as indicated by its country and region (us). The company operates globally, discovering, developing, and commercializing medicines in areas of unmet medical need worldwide. Its products are used to treat HIV-1 infection, chronic hepatitis B and C, primary biliary cholangitis, certain cancers, serious fungal infections, and COVID-19. Through collaborations with various partners, including Shenzhen Pregene Biopharma, Arcus Biosciences, Merck Sharp & Dohme, and others, Gilead extends its reach across multiple therapeutic areas and geographies.

Gilead Sciences has numerous collaboration agreements to expand its research and development. Notable partners include Shenzhen Pregene Biopharma, Arcus Biosciences, Merck Sharp & Dohme, Janssen Sciences Ireland, Japan Tobacco, Everest Medicines, Merck & Co, Tentarix Biotherapeutics, and Assembly Biosciences. It also has a research collaboration with Merus N.V. for discovering novel dual tumor-associated antigens targeting trispecific antibodies, and a collaboration with Terray Therapeutics for small molecule therapies. Additionally, Gilead works with LEO Pharma on development and manufacturing. The company is actively developing immunotherapies for cancer and incurable diseases, leveraging these partnerships to advance its pipeline.